PLX
Protalix BioTherapeutics, Inc.
NYSE AmericanUSDEQUITY
DELAYED
Last price
2.28
▼ 0.10 (4.18%)
MARKET · —
Price
Open
2.39
Prev close
2.38
Day high
2.44
Day low
2.35
Volume
600.18K
Market cap
—
P/E (TTM)
—
52W range
1.52 – 3.19
Trailing performance
Returnvs SPY
1W
+7.21%
+8.6%
1M
+0.42%
-3.3%
3M
+17.24%
+14.1%
6M
-22.22%
-33.3%
YTD
+32.22%
+19.9%
1Y
+51.59%
+31.6%
3Y
+20.81%
-53.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
2.38
-4.39% from price
SMA 20
2.38
+0.17% from price
SMA 50
2.32
+2.71% from price
SMA 100
2.21
+3.16% from price
SMA 200
2.22
+7.08% from price
EMA 12
2.37
-3.84% from price
EMA 26
2.36
-3.39% from price
EMA 50
2.32
-1.70% from price
RSI (14)
51.4
Neutral
MACD (12,26,9)
0.01
Hist -0.01
ATR (14)
0.12
5.16% of price
Realised vol 30D
51.1%
Annualised
Bollinger upper
2.55
20, 2σ
Bollinger lower
2.20
20, 2σ
50 / 200 cross
Golden
2.32 vs 2.22
Trend bias
Above 200
+7.08%
Risk profile
Beta vs SPY
1.30
More volatile than market
Correlation to SPY
0.26
Largely independent
Realised vol 30D
51.1%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-39.7%
Peak to trough
Max drawdown 5Y
-73.2%
Peak to trough
ATR 14
0.12
5.16% of price
Beta (reported)
—
5Y monthly, from filing
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Protalix BioTherapeutics, Inc. Q2 2026 Earnings Call Summary
Moby · 9d ago
PLX: Elfabrio Estimates Up
Zacks Small Cap Research · 9d ago
Protalix BioTherapeutics Inc (PLX) (Q2 2026) Earnings Call Highlights: Net Income Surges to $3. ...
GuruFocus.com · 10d ago
Protalix: Q2 Earnings Snapshot
Associated Press · 10d ago
Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results
PR Newswire · 10d ago
Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026
PR Newswire · 17d ago
3 Penny Stocks With Market Caps Larger Than $100M To Consider
Simply Wall St. · 88d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.